Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
PepGen is harnessing the power of our Enhanced Delivery Oligonucleotide technology to solve the challenge of getting oligonucleotides to where they need to be to work, and to realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases
Total Funding: $159.6 M
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2018
Dec 2021
- PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations
Nov 2021
- PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development
Oct 2021
- PepGen Appoints Noel Donnelly as Chief Financial Officer
Oct 2021
- PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Pepgen
Executive Assistant
Cambridge , MA
Research Associate
Cambridge , MA
Senior Scientist , Analytical Development
Cambridge , MA
Senior Director
Cambridge , MA
Research Associate -2
Cambridge , MA
